The grant, plainly. On August 18, 2020, The Scripps Research Institute was issued US10745456B2, covering GPCR agonist polypeptides. The CPC tags — C07K 14/605 (GLP-1 family), A61P 3/10 (diabetes), C12N 15/85 — locate it at the discovery end of the metabolic-receptor stack, where institutional IP is generated before any company exists to commercialize it.
Why a financing desk traces IP to its source: a great deal of small-cap biotech is built on in-licensed academic patents. The economics of a thin balance sheet often depend on milestone and royalty obligations flowing back to an institution like Scripps. Understanding where the IP originated is understanding the encumbrances on a young company's value.
The cautionary read: early-stage receptor IP is foundational but unproven. A polypeptide-agonist grant from a research institute is a starting asset, not a product, and the runway of any licensee is still governed by cash and burn. The license terms — upfronts, milestones, royalty step-ups — are a real claim on future proceeds that a holder should price in.
What the grant does not show: which company, if any, licensed it, on what terms, or with what runway. Those facts live in corporate filings and the license agreement, not the patent. The grant establishes the existence and scope of the underlying asset.
The takeaway: when scanning thin-balance-sheet metabolic names, trace the foundational IP back to its institutional source and price the license obligations. Scripps' August 2020 GPCR-agonist grant is a dated example of where the metabolic-receptor value chain begins.